Lisata Therapeutics Inc Investor Relations Material
Latest events
Q1 2024
Lisata Therapeutics Inc
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Lisata Therapeutics Inc
Access all reports
Lisata Therapeutics Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing cellular therapies to reverse disease, promote regeneration and halt disease progression. Its product candidates include HONEDRA, a cell therapy product candidate that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; CLBS201, a CD34+ cell therapy for pre-dialysis patients with chronic kidney disease; AB1250-H, an investigational drug product candidate for acute myocardial infarction (AMI) patients who have undergone percutaneous coronary intervention (PCI); and VB6100, an investigational gene therapy product candidate designed to treat demyelinating disorders such as multiple sclerosis
Key slides for Lisata Therapeutics Inc
Q1 2024
Lisata Therapeutics Inc
Q1 2024
Lisata Therapeutics Inc
Latest articles
The Birkin Bag: The Story Behind the World's Most Desired Handbag
How the Birkin bag became the world's most sought-after handbag where even the wealthy must earn the right to own one.
12 Jul 2024
The 10 Largest Semiconductor Companies in the World
Discover the top 10 semiconductor companies by market cap, exploring their innovations and business models shaping the tech landscape.
10 Jul 2024
The Rise of Nubank: Changing Latin American Finance
Discover how Nubank revolutionized Latin American banking with innovation, backed by top investors like Berkshire Hathaway.
9 Jul 2024
Ticker symbol
LSTA
Country
🇺🇸 United States